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546a Tuesday, February 18, 2014have been identified as the targets of these drugs, but it is unknown how anes-
thetics exert their effects. Previous simulations from our group have uncovered
a membrane-dependent entrance mechanism, whereby the anesthetic partitions
to the membrane prior to binding a transmembrane site identified in crystal
structures. To probe for additional binding sites unbiasedly and corroborate
the membrane-dependent entrance tunnel previously discovered, we have
used the "flooding" technique where the system is flooded with multiple copies
of the drug to increase the probability of observing binding events. Our simu-
lations elucidated not only the binding region indicated in crystal structures, but
also a novel second transmembrane binding site (TM2) observed consistently
across all subunits. The TM2 site is directly between the crystal structure site
(TM1) and the entrance tunnel elucidated in our simulations. Free energy
calculations show binding to the TM2 site increases the affinity of anesthetic
for the TM1 site in addition to acting as a physical barrier blocking the exit
of anesthetic from the protein. Moreover, anesthetic binding to the TM1/
TM2 sites induces an iris-like tilting of the M2 helix, as observed in our previ-
ous simulations, leading to constriction and dehydration of the conduction pore.
Utilizing umbrella sampling, this conformational change significantly increases
the barrier to conduction, prohibiting ion conduction in the dehydrated state.
Lastly, measurements of non-equilibrium work show that desflurane only mini-
mally perturbs the work required to induce constriction of the pore, while
greatly increasing the work needed for the dehydrated to open state transition.
This suggests that anesthetics stabilize the dehydrated state, but do not destabi-
lize the open state.
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Pentameric ligand-gated ion channels (pLGICs) mediate fast synaptic transmis-
sion. pLGIC activation is initiated by agonist binding to the orthosteric site in the
extracellular domain (ECD), which promotes rapid opening of a membrane-
embedded ion-conducting pore. Prolonged agonist exposure leads to pLGIC
desensitization, which results in channel closure. Eukaryotic pLGICs open in
the sub-millisecond to millisecond timescale, and transition into desensitized
closed states in tens of milliseconds. To date, we have limited knowledge of
the structural elements that underlie the rapid kinetics of activation and desen-
sitization in pLGICs.We previously showed that eukaryotic pLGICs are charac-
terized by loose packing of the ECD hydrophobic core, due to cavities created at
two conserved sites by buried side-chains of either polar residues (threonine and
serine in nicotinic receptors, nAChRs) or alanines (in GABA-A receptors), and
that increasing the packing of the ECD core at these two sites slowed agonist-
induced current activation and desensitization rates (Dellisanti et al., Nat
Neurosci 2007; Dellisanti and Czajkowski, J Biol Chem 2011). Interestingly,
prokaryotic pLGICs, like proton-activated GLIC, activate and desensitize
slowly and have a tightly packed ECD core. Here, we generated loose packing
mutants of GLIC by mutating V38 and V109 (aligned to nAChR-a1 T52 and
S126) to either alanines or threonine and serine, respectively. We expressed
the GLIC mutants in Xenopus oocytes and monitored the effects of these
mutations on proton-elicited currents using two-electrode voltage clamp. The
loose packingGLICmutants had 2- to 3-fold faster current activation and desen-
sitization rates compared to wild-type GLIC. The effects were larger when both
valines (V38AV109A and V38TV109S mutants) were mutated. Our data sug-
gest loose packing of the ECD core is directly implicated in fast activation
and desensitization of eukaryotic pLGICs.
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Pentameric ligand gated ion channels (pLGICs), especially anion-selective
GABAARs, are major targets of general anesthetic (GA) drugs. GAs mediate
their actions by binding in the transmembrane domain (TMD) of pLGICs,
which potentiates anion-selective pLGIC currents and inhibits cation-
selective pLGICs. Recently, crystal structures of prokaryotic cation-selective
pLGIC homologs, GLIC and ELIC, have been solved with several GAs bound.
High-resolution structures that reveal how GA’s interact with anion-selective
channels such as the GABAAR are not available, which justifies a quest for
pLGIC constructs that preserve GA positive modulation and are amenable
for structural studies.
Here, we report the construction and characterization of a GLIC-GABAr
chimeric pLGIC that is positively modulated by the GA pentobarbital. We
fused the extracellular domain (ECD) of the prokaryotic proton-gated homo-pentameric channel GLIC with the eukaryotic GABAr subunit TMD.
GABAAR r1 subunits form homopentameric channels making them ideal
for constructing chimeras with GLIC. The GLIC-r chimeric construct formed
functional proton-gated channels when expressed in Xenopus oocytes. The
reversal potential of the chimeric channels was 31mV, which is similar to
the reversal potential of GABAr receptors suggesting that the channel is
chloride-selective. GABAr receptors are normally insensitive or inhibited by
GAs but a point mutation in GABAr TMD W328M converts it to a channel
that is positively modulated by pentobarbital. When this mutation was made
in the GLIC-GABAr chimeric construct, the mutant chimeric channel was
directly gated by pentobarbital and proton-mediated currents were potentiated
by pentobarbital. Protocols for expressing and purifying high levels of the
GLIC-GABAr chimeric channel protein are currently being developed.
2764-Pos Board B456
Allosteric Modulation of GABA-A Receptors by Different Drugs
Borna Ghosh, Tzu-Wei Tsao, Cynthia Czajkowski.
Neuroscience, University of Wisconsin, Madison, Madison, WI, USA.
Understanding how drugs allosterically modulate GABA-A receptor
(GABAAR) channel function remains a challenge. Anesthetic drugs like etomi-
date, propofol and pentobarbital bind at transmembrane domain (TMD) inter-
subunit interfaces at different locations. Benzodiazepines bind at the ag
interface in the extracellular domain (ECD) and neurosteroids are believed to
bind within the a-subunit TMD helix bundle. A common feature of these drugs
is that they potentiate GABA-induced currents. Here, we examined whether
structural mechanisms underlying their functional effects are distinct. We
monitored motions induced individually by these drugs at each inter-subunit
TMD interface and also tested whether modulation caused by pairs of drugs
binding to distinct sites are additive or super-additive.
We individually introduced a cysteine in the M1 helices of each subunit at
a1I227, b2L223 and g2LI238 to probe the different inter-subunit interfaces.
We expressed wild-type and mutant a1b2g2L GABAARs in Xenopus oocytes
and measured rates of modification of the substituted cysteines in the absence
and presence of GABA and different allosteric modulators: the anesthetics
pentobarbital (PB) and etomidate, the neurosteroid THDOC and the benzodiaz-
epine flurazepam. GABA activation significantly increased MTSEA modifica-
tion of aI227C, bL223C and gI238C. PB activation increased modification of
aI227C and gI238C but not bL223C. Modulating concentrations of PB or
etomidate had no effects. THDOC significantly increased the rate of modifica-
tion of bL223C whereas flurazepam increased gI238C modification. We found
that potentiation of EC10 GABA currents by combining modulating concentra-
tions of THDOC and flurazepam was the sum of the potentiation produced by
the two drugs individually. Combining PB and THDOC produced potentiation
more than the sum of the potentiation produced by the two drugs individually.
Our data suggests that drugs binding to different sites act via distinct mecha-
nisms. Further analysis is underway to determine if these mechanisms are inde-
pendent or coupled.
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Despite the wide prescription of drugs targeting postsynaptic g-aminobutyric
acid receptors (GABAARs) for seizure and epilepsy, mechanisms by which
those drugs exert their effects on GABAAR are poorly understood. This is
mainly attributed to the unavailability of crystal structure of the receptor and
the various assembly of 19 different subunits (a1- a6, b1-b3, g1-g3, d, ε, p,
q, r1-r3). Here, we studied the effects of two anticonvulsants on the recombi-
nant a1b3g2 GABAAR using whole-cell current recordings combined with
rapid kinetic techniques. Our results showed that pentylenetetrazole (PTZ), a
compound used to artificially induce convulsive effect in animal models, is a
mixed inhibitor of the receptor. Anticonvulsant ethosuximide (ES) and the
major metabolite (a-methyl-a-pheny-succinimide, MPS) of another anticon-
vulsant methsuximide (MS) were found to alleviate the inhibition of the recep-
tor by PTZ, while MS itself doesn’t. Those data suggest that the enhancement
of postsynaptic GABAAR response is one of the mechanisms of the anticonvul-
sant effect of ES and MS. T-type calcium channel was suggested to be one of
the targets of ES.
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